What does FARMALINE do?

FARMALINE is a pharmacy in Gent. Private Limited, started on 17 December 2010, 1 establishment.

What is the address of FARMALINE?

The registered office of FARMALINE is located at Nieuwevaart 151, 9000 Gent.

Is FARMALINE still active?

Yes. According to the CBE (29 October 2026) FARMALINE is active, legal situation “Normale toestand”, started on 17 December 2010.

Is FARMALINE registered on Peppol?

Yes, FARMALINE is registered on the Peppol network with ID 0208:0832002751.

What is the enterprise number of FARMALINE?

The enterprise number of FARMALINE is BE0832002751.

When was FARMALINE founded?

FARMALINE was founded on 17 December 2010.

Who are the directors of FARMALINE?

According to the 2025 annual accounts, the directors of FARMALINE are: Coop-Apotheken CVSO.

Is FARMALINE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 17 December 2010; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did FARMALINE make in 2025?

FARMALINE posted a profit after taxes of € 9,090 in financial year 2025.

What is the revenue of FARMALINE?

As a small company, FARMALINE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 12,450.

FARMALINE (Private Limited) - Gent - BE0832002751

Dossier FARMALINE, printed on 29 October 2026 from databakkes.be/en/0832002751/farmaline. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

FARMALINE from Gent, company number BE0832002751, closed financial year 2025 with a result of € 9,090 after tax. For that financial year FARMALINE recorded a gross margin of € 12,450 and equity of € 35,761. Compared with financial year 2024, the result moved from € 7,343 to € 9,090. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 3, 2026.

What it is worth Growing

€ 35,761

▲ 34% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 9,090

▲ 24% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 1,033

▼ 74% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 23,361.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 1,850

▲ 4% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 2,353

▼ 17% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 41,521 Gross margin 2022: € 41,521 First fiscal year in the series	€ 38,948 Gross margin 2023: € 38,948 ▼ 6% vs 2022 (€ 41,521) Unfavourable step	€ 40,171 Gross margin 2024: € 40,171 ▲ 3% vs 2023 (€ 38,948) Favourable step	€ 12,450 Gross margin 2025: € 12,450 ▼ 69% vs 2024 (€ 40,171) Unfavourable step	▼ 69%
Profit after taxes	€ 3,729 Profit after taxes 2022: € 3,729 First fiscal year in the series	€ 1,603 Profit after taxes 2023: € 1,603 ▼ 57% vs 2022 (€ 3,729) Unfavourable step	€ 7,343 Profit after taxes 2024: € 7,343 ▲ € 5,740 vs 2023 (€ 1,603) Favourable step	€ 9,090 Profit after taxes 2025: € 9,090 ▲ 24% vs 2024 (€ 7,343) Favourable step	▲ 24%
Equity	€ 17,725 Equity 2022: € 17,725 First fiscal year in the series	€ 19,328 Equity 2023: € 19,328 ▲ 9% vs 2022 (€ 17,725) Favourable step	€ 26,671 Equity 2024: € 26,671 ▲ 38% vs 2023 (€ 19,328) Favourable step	€ 35,761 Equity 2025: € 35,761 ▲ 34% vs 2024 (€ 26,671) Favourable step	▲ 34%
Total debts	€ 70,247 Total debts 2022: € 70,247 First fiscal year in the series	€ 36,439 Total debts 2023: € 36,439 ▼ 48% vs 2022 (€ 70,247) Favourable step	€ 4,601 Total debts 2024: € 4,601 ▼ 87% vs 2023 (€ 36,439) Favourable step	€ 4,203 Total debts 2025: € 4,203 ▼ 9% vs 2024 (€ 4,601) Favourable step	▼ 9%
Cash	€ 11,333 Cash 2022: € 11,333 First fiscal year in the series	€ 12,905 Cash 2023: € 12,905 ▲ 14% vs 2022 (€ 11,333) Favourable step	€ 3,919 Cash 2024: € 3,919 ▼ 70% vs 2023 (€ 12,905) Unfavourable step	€ 1,033 Cash 2025: € 1,033 ▼ 74% vs 2024 (€ 3,919) Unfavourable step	▼ 74%
Retained profit	€ 5,325 Retained profit 2022: € 5,325 First fiscal year in the series	€ 6,928 Retained profit 2023: € 6,928 ▲ 30% vs 2022 (€ 5,325) Favourable step	€ 14,271 Retained profit 2024: € 14,271 ▲ 106% vs 2023 (€ 6,928) Favourable step	€ 23,361 Retained profit 2025: € 23,361 ▲ 64% vs 2024 (€ 14,271) Favourable step	▲ 64%
Balance sheet total	€ 87,972 Balance sheet total 2022: € 87,972 First fiscal year in the series	€ 55,768 Balance sheet total 2023: € 55,768 ▼ 37% vs 2022 (€ 87,972) Unchanged	€ 31,272 Balance sheet total 2024: € 31,272 ▼ 44% vs 2023 (€ 55,768) Unchanged	€ 39,964 Balance sheet total 2025: € 39,964 ▲ 28% vs 2024 (€ 31,272) Unchanged	▲ 28%

Key figures of FARMALINE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to FARMALINE?

What happened at FARMALINE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 3, 2026 New annual accounts for financial year 2025: profit of € 9,090 (▲ 24% vs 2024). Source: NBB ↗
2024 Coop-Apotheken CVSO became a director. NBB
Jan 12, 2011 New establishment in Deinze. KBO
Dec 17, 2010 Start of the company according to the CBE. KBO

In short

From € 3,729 profit in 2022 to € 9,090 profit in 2025.

Paid € 7,187 in corporate taxes since 2022.

Best year ever: 2025, with € 9,090 profit.

Original PDFs at the National Bank ↗

Management

COOP-APOTHEKEN 99.5%

The stake of COOP-APOTHEKEN comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

FARMALINE

Behind FARMALINE is Coop-Apotheken CVSO. The shares are held by COOP-APOTHEKEN (99.5%).

Directors

According to the 2025 annual accounts

Coop-Apotheken CVSO

Director · represented by Eveline De Laender

Also active at: TANGHE-DE CLERCQ, Apotheek De Smet F.

since 2024

Shareholders

COOP-APOTHEKEN

99.5%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Nieuwevaart 151

9000 Gent

2.194.800.489

Stationsstraat 51

9850 Deinze

Active since 12 January 2011

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 8 companies are registered at this address.

All companies at this address →

IMMOCOV

€ 2.2 million gross margin · 2025

VOORUIT NR. 1

€ 3.6 million revenue · 2025

Fonds Eduard Anseele

COOP-APOTHEKEN same network

€ 85.3 million revenue · 2025

COOP APOTHEKEN

+3 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0832.002.751

VAT number

BE 0832.002.751

Registered office

Nieuwevaart 151, 9000 Gent

Names & denominations

FARMALINE

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

17 December 2010

Peppol

Active · Active since 14 Dec 2025

Activities · NACE

Detailhandel in farmaceutische producten

Overige rechtskundige dienstverlening

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels

View on CBE Public ↗ Annual accounts (NBB) ↗

FARMALINE

Financials

What happened to FARMALINE?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions